Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Abstract Background Passive immunization against RSV (Respiratory Syncytial Virus) is given in most western countries (including Israel) to infants of high risk groups such as premature babies, and infants with Congenital Heart Disease or Congenital Lung Disease. However, immunoprophylaxis costs are...

Full description

Bibliographic Details
Main Authors: Gary M. Ginsberg, Eli Somekh, Yechiel Schlesinger
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Israel Journal of Health Policy Research
Subjects:
Cost-utility analysis
RSV
Immunoprophylaxis
Online Access:http://link.springer.com/article/10.1186/s13584-018-0258-4

Internet

http://link.springer.com/article/10.1186/s13584-018-0258-4

Similar Items